Clinical Trials Directory

Trials / Completed

CompletedNCT00424528

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
235 (actual)
Sponsor
Sumitomo Pharma America, Inc. · Industry
Sex
All
Age
45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).

Detailed description

This study is a multicenter, randomized, modified-blind, double-dummy two-week parallel-group efficacy and safety study of arformoterol tartrate inhalation solution twice daily, tiotropium inhalation powder once daily and arformoterol tartrate inhalation solution twice daily and tiotropium inhalation powder once daily (dosed sequentially) in subjects with COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

Interventions

TypeNameDescription
DRUGArformoterol Tartrate Inhalation SolutionArformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
DRUGTiotropiumPlacebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
DRUGArformoterol and TiotropiumArformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
DRUGPlaceboPlacebo inhalation solution and placebo inhalation powder

Timeline

Start date
2006-12-01
Primary completion
2007-10-01
Completion
2007-10-01
First posted
2007-01-19
Last updated
2012-06-04
Results posted
2009-04-02

Locations

28 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00424528. Inclusion in this directory is not an endorsement.